{"id":"W4295817567","doi":"10.1016/j.annonc.2022.07.861","title":"735MO Updated safety and efficacy from SURPASS, the phase I trial of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in previously treated patients with unresectable or metastatic tumors","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; CD8; Cancer; Adverse effect; Leukapheresis; Immunotherapy; Antigen; Immunology; CD34","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001521514,0.000353701,0.0007172655,0.0004534104,0.0003490286,0.001342743,0.0005073751,0.0007733646,0.01246071],"category_scores_gemma":[0.002310492,0.0001922693,0.0008987114,0.0004144583,0.0002326582,0.0007324528,0.0002958189,0.001843503,0.002142954],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001008145,"about_ca_system_score_gemma":0.001390367,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001710975,"about_ca_topic_score_gemma":0.007270614,"domain_scores_codex":[0.9994998,0.0001446853,0.00003443778,0.00006793398,0.0001800845,0.0000730855],"domain_scores_gemma":[0.9989941,0.0003437213,0.0001624584,0.000087277,0.000187244,0.0002253503],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.04163408,0.001630233,0.009238733,0.001344893,0.001361484,0.000406299,0.00009357665,0.001831414,0.02090304,0.002611432,0.1892766,0.7296681],"study_design_scores_gemma":[0.03812483,0.02789843,0.05444176,0.0006928123,0.00391655,0.001659141,0.00008540217,0.002920797,0.01668175,0.00333311,0.8501441,0.0001011988],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.4647724,0.1267003,0.007700359,0.07162297,0.008834513,0.002440678,0.08863335,0.002489094,0.2268063],"genre_scores_gemma":[0.7582375,0.03940543,0.00819924,0.04354385,0.005010121,0.001073156,0.05843968,0.0004582264,0.08563283],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01246071,"threshold_uncertainty_score":0.04168522,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1135227417432151,"score_gpt":0.3761822592764473,"score_spread":0.2626595175332322,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}